The AI in Drug Discovery Market is gaining momentum as pharmaceutical companies seek faster, more efficient, and data-driven approaches to discovering new medicines. Market Research Future estimates that the industry will grow from USD 2.81 billion in 2025 to USD 23.95 billion by 2035, representing a CAGR of 23.9%.

One of the primary drivers is the rising cost and complexity of traditional drug development. AI can help researchers analyze molecular information, identify promising targets, prioritize compounds, and predict potential outcomes earlier in the development process. These capabilities can help reduce unnecessary laboratory experimentation and improve research productivity.

The increasing availability of biomedical data is creating another major opportunity. Genomic databases, clinical information, protein structures, chemical libraries, and scientific literature provide extensive datasets for AI models. Natural language processing can help researchers extract information from scientific publications, while machine learning can support predictive analysis.

AI-powered rare-disease research is an emerging opportunity because computational approaches can help identify potential targets and repurpose existing compounds for smaller patient populations. Cloud-based AI-as-a-Service platforms may also expand access among mid-sized pharmaceutical and biotechnology companies.

Asia-Pacific represents another important opportunity, with increasing investments in pharmaceutical research and artificial intelligence. India and China are developing growing ecosystems of pharmaceutical companies, contract research organizations, and AI technology providers.

The combination of lower computational barriers, improved algorithms, and expanding datasets is expected to support continued market growth.